Blackstone Inc
FULC icon

Blackstone Inc’s Fulcrum Therapeutics FULC Stock Holding History

Blackstone Inc’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,216
Closed -$181K – 186
2024
Q1 		$181K Hold
19,216
– – ﹤0.01% 169
2023
Q4 		$130K Hold
19,216
– – ﹤0.01% 155
2023
Q3 		$85.3K Hold
19,216
– – ﹤0.01% 150
2023
Q2 		$63.4K Hold
19,216
– – ﹤0.01% 148
2023
Q1 		$54.8K Hold
19,216
– – ﹤0.01% 162
2022
Q4 		$140K Buy
+19,216
New +$125K ﹤0.01% 161
2022
Q2 		– Sell
-9,500
Closed -$225K – 256
2022
Q1 		$225K Buy
+9,500
New +$134K ﹤0.01% 215
2021
Q4 		– Sell
-4,758
Closed -$134K – 552
2021
Q3 		$134K Buy
+4,758
New +$90.2K ﹤0.01% 499

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Blackstone Inc's FULC Position: Q2 2024 in Review

Blackstone Inc sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 19,216 shares — an estimated $181K sold.

Blackstone Inc first reported a position in FULC in Q3 2021 and held it in 8 quarters. The position peaked at $225K in Q1 2022. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Blackstone Inc reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Blackstone Inc sold 19,216 Fulcrum Therapeutics shares in Q2 2024, an estimated $181K.
  • Blackstone Inc first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 8 quarters.
  • Blackstone Inc's Fulcrum Therapeutics position peaked at $225K in Q1 2022.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.